PT1957074E - Formulações de quinolinonas - Google Patents

Formulações de quinolinonas Download PDF

Info

Publication number
PT1957074E
PT1957074E PT68385905T PT06838590T PT1957074E PT 1957074 E PT1957074 E PT 1957074E PT 68385905 T PT68385905 T PT 68385905T PT 06838590 T PT06838590 T PT 06838590T PT 1957074 E PT1957074 E PT 1957074E
Authority
PT
Portugal
Prior art keywords
quinolinones
formulations
Prior art date
Application number
PT68385905T
Other languages
English (en)
Inventor
Joyce Chou
Augustus Okhamafe
Patricia Frech
Rampurma Gullapalli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1957074E publication Critical patent/PT1957074E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
PT68385905T 2005-11-29 2006-11-29 Formulações de quinolinonas PT1957074E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74057705P 2005-11-29 2005-11-29
US74131705P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
PT1957074E true PT1957074E (pt) 2014-06-25

Family

ID=38024178

Family Applications (1)

Application Number Title Priority Date Filing Date
PT68385905T PT1957074E (pt) 2005-11-29 2006-11-29 Formulações de quinolinonas

Country Status (23)

Country Link
US (2) US20080293738A1 (pt)
EP (2) EP2772257A1 (pt)
JP (1) JP2009517481A (pt)
KR (1) KR20080074143A (pt)
CN (1) CN102670530A (pt)
AR (1) AR062545A1 (pt)
AU (1) AU2006320591B2 (pt)
BR (1) BRPI0619370A2 (pt)
CA (1) CA2627544C (pt)
CL (1) CL2010000387A1 (pt)
EC (1) ECSP088467A (pt)
ES (1) ES2467162T3 (pt)
IL (1) IL190865A0 (pt)
MA (1) MA29969B1 (pt)
MY (1) MY148529A (pt)
NO (1) NO20082938L (pt)
NZ (1) NZ567550A (pt)
PE (1) PE20070760A1 (pt)
PL (1) PL1957074T3 (pt)
PT (1) PT1957074E (pt)
RU (1) RU2433826C2 (pt)
TW (1) TW200730176A (pt)
WO (1) WO2007064719A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
UY33472A (es) * 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
BR112014017985A8 (pt) 2012-01-31 2017-07-11 Novartis Ag Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
JP7469308B2 (ja) 2018-12-06 2024-04-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規の医薬製剤

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3663606A (en) * 1966-06-21 1972-05-16 Mitsui Toatsu Chemicals Organic imino-compounds
DE2363459A1 (de) 1973-12-20 1975-06-26 Basf Ag Neue fluoreszierende chinolinverbindungen
US4119105A (en) 1977-01-31 1978-10-10 Olin Corporation Air flow limiting filter
JPH0699497B2 (ja) 1987-04-16 1994-12-07 富士写真フイルム株式会社 光重合性組成物
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP3161780B2 (ja) 1991-09-30 2001-04-25 東レ・ダウコーニング・シリコーン株式会社 α，ω−ジヒドロキシフルオロアルキルメチルポリシロキサンの製造方法
JP3142378B2 (ja) 1992-06-22 2001-03-07 ティーディーケイ株式会社 有機ｅｌ素子
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
JPH0743896A (ja) 1993-07-28 1995-02-14 Toyobo Co Ltd 光重合性組成物
JPH0829973A (ja) 1994-07-11 1996-02-02 Toyobo Co Ltd 光重合性組成物
JP3441246B2 (ja) 1995-06-07 2003-08-25 富士写真フイルム株式会社 光重合性組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
DE19610723A1 (de) 1996-03-19 1997-09-25 Bayer Ag Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen
CN1226245A (zh) 1996-06-20 1999-08-18 德克萨斯州大学系统董事会 具有药理活性的化合物,其制备方法及其用途
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
US6138605A (en) 1998-08-05 2000-10-31 Seascape Systems Limited Access and evacuation apparatus with articulated arm
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
CN101053573A (zh) 2000-01-19 2007-10-17 帕卡什·S·吉尔 针对反义vegf寡核苷酸的方法和组合物
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
CA2402589C (en) * 2000-03-07 2011-02-01 Sanjay Garg Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
WO2004018419A2 (en) 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
EP1682529A4 (en) 2003-11-07 2010-06-30 Novartis Vaccines & Diagnostic METHODS FOR SYNTHESIS OF QUINOLINONE COMPOUNDS
EP1718306A2 (en) * 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
MX2007014612A (es) * 2005-05-18 2008-01-17 M & G Polimeri Italia Spa Composicion de poliester.
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts

Also Published As

Publication number Publication date
PE20070760A1 (es) 2007-10-04
MA29969B1 (fr) 2008-11-03
WO2007064719A3 (en) 2007-08-16
CN102670530A (zh) 2012-09-19
ECSP088467A (es) 2008-06-30
MY148529A (en) 2013-04-30
EP1957074B1 (en) 2014-03-19
NO20082938L (no) 2008-06-30
US20120276200A1 (en) 2012-11-01
TW200730176A (en) 2007-08-16
RU2433826C2 (ru) 2011-11-20
CA2627544C (en) 2015-07-07
JP2009517481A (ja) 2009-04-30
AU2006320591A1 (en) 2007-06-07
AR062545A1 (es) 2008-11-19
ES2467162T3 (es) 2014-06-12
NZ567550A (en) 2011-08-26
RU2008126384A (ru) 2010-01-10
PL1957074T3 (pl) 2014-08-29
BRPI0619370A2 (pt) 2011-09-27
CL2010000387A1 (es) 2010-08-06
CA2627544A1 (en) 2007-06-07
IL190865A0 (en) 2008-11-03
KR20080074143A (ko) 2008-08-12
US20080293738A1 (en) 2008-11-27
EP1957074A2 (en) 2008-08-20
EP2772257A1 (en) 2014-09-03
AU2006320591B2 (en) 2010-06-03
WO2007064719A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
GB2424581B (en) Formulations
GB2435419B (en) Formulations
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
GB0605780D0 (en) Formulations
IL190865A0 (en) Formulations of quinolinones
PL2402005T3 (pl) Formulacje nalbufiny o przedłużonym uwalnianiu
EP1912499A4 (en) PREPARATION OF MONTELUKAST
GB0505569D0 (en) Formulations
GB0718409D0 (en) Formulations
GB0615108D0 (en) Novel formulations
GB0610336D0 (en) Formulations
HK1161122A1 (en) Use of 24-norudca 24-norudca
ZA200803213B (en) Formulations of quinolinones
GB0718404D0 (en) Formulations
ZA200807682B (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0519090D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0520388D0 (en) Formulations
GB0518878D0 (en) Formulations